Vitiligo is an autoimmune depigmentation disorder. Narrowband ultraviolet B (NB-UVB) phototherapy is currently the standard of care for generalized vitiligo. The combination of visible light (VL) with UVA1 (VL+UVA1) has recently been shown to induce skin pigmentation. This pilot study aims to compare the efficacy of VL+UVA1 versus NB-UVB phototherapy in subjects with vitiligo. Preliminary findings suggest a more robust erythematous response post-irradiation at VL+UVA1 site when compared to NB-UVB sites. Study results will provide information regarding optimal wavebands and associated parameters, including irradiance and dosing, that can result in skin repigmentation in vitiligo patients.